Long-term results of surgical subxiphoid pericardial drainage.

A series of 64 consecutive patients who underwent surgical subxiphoid drainage of pericardial effusion over an 11-year period, was analysed both for recurrence of pericardial pathology and survival. The mean follow-up time was 4 years (6 months to 10 years). Twelve patients had recurrent effusion (18%), all except one within 6 months: six patients (9%) had another drainage procedure which was the definitive treatment except in one terminal cancer patient with intractable malignant effusion who died of cardiac tamponade. The remaining six recurrent effusions could be treated conservatively. One patient with idiopathic effusion developed late constrictive pericarditis. Patients with underlying malignancy (n = 26) had significantly worse actuarial survival than the others (actuarial survival at 1 and 5 years of 51% and 0% vs 87% and 76%, respectively). However, their probability of remaining free of recurrence did not differ significantly (actuarial freedom at 1 year of 89% vs 76%). In conclusion, subxiphoid drainage provides a simple, safe and expeditious treatment of most symptomatic pericardial effusions with one in ten patients requiring a repeat drainage for recurrence. In particular, it offers a good palliation in most patients with underlying neoplastic disease. Routine echocardiography is recommended at one and six months to catch most of the recurrent effusions.